MIST vs RDY

MIST Core

Annual filing released 2025-03-13 · GPT 6 Luna

prevent new investors from influencing significant corporate decisions. 6 Table of Contents PART I ITEM 1. BUSINESS Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our objective is to commercialize and develop CARDAMYST (also known as etripamil) in the United States as a fast-acting, portable nasal spray treatment for use by patients anywhere, anytime an attack of supraventricular tachycardia, or “SVT” occurs. We are also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate, or “AFib-RVR.” CARDAMYSTTM (etripamil) nasal spray

Table of Contents Milestone Pharmaceuticals Inc. Notes to Consolidated Financial Statements (in thousands of US dollars, except share and per share data) 1 Organization and Nature of Operations Milestone Pharmaceuticals Inc., or “Milestone,” or the “Company,” is a biopharmaceutical company incorporated under the Business Corporations Act of Québec. Milestone is focused on the development and commercialization of innovative cardiovascular medicines. Milestone’s lead product candidate, etripamil, is a novel, potent short-acting calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

RDY Material

Annual filing released 2025-06-06 · GPT 6 Luna

This segment consists of our other business operations which includes our wholly-owned subsidiaries, Aurigene Oncology Limited (“AOL”) (formerly Aurigene Discovery Technologies Limited) and our Proprietary Products business. AOL is a specialized biotechnology company engaged in discovery and early clinical development of novel, best-in-class therapies in the fields of oncology and inflammation. AOL works with established pharmaceutical and biotechnology companies through customized models of drug-discovery collaborations. Our Proprietary Products business is focused on the research, development and commercialization of differentiated formulations and we derive revenues from such assets through event specific milestones and subsequent royalties, if any. Our key markets include the United States, India, Russia and other countries of the former Soviet Union, and Europe. OUR STRATEGY

AOL is a clinical stage biotech company committed to developing innovative and effective cancer therapeutics. AOL has successfully discovered 21 novel chemical entities for clinical development. Some of these molecules were developed in collaboration with global pharmaceutical and biotechnology companies while others were developed independently. We have out-licensed several first-in-class and best-in-class assets to pharmaceutical and biotechnology companies for global clinical development, while undertaking clinical proof of concept studies for a few programs on our own. Over the years, AOL has developed multiple discovery platforms, including kinase inhibitors, targeted protein degraders, antibody engineering and cell and gene therapy, resulting in a pipeline of first-in-class and best-in-class assets. Proprietary Products:

MIST Core

Annual filing released 2025-03-13 · GPT 6 Luna

prevent new investors from influencing significant corporate decisions. 6 Table of Contents PART I ITEM 1. BUSINESS Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our objective is to commercialize and develop CARDAMYST (also known as etripamil) in the United States as a fast-acting, portable nasal spray treatment for use by patients anywhere, anytime an attack of supraventricular tachycardia, or “SVT” occurs. We are also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate, or “AFib-RVR.” CARDAMYSTTM (etripamil) nasal spray

Table of Contents Milestone Pharmaceuticals Inc. Notes to Consolidated Financial Statements (in thousands of US dollars, except share and per share data) 1 Organization and Nature of Operations Milestone Pharmaceuticals Inc., or “Milestone,” or the “Company,” is a biopharmaceutical company incorporated under the Business Corporations Act of Québec. Milestone is focused on the development and commercialization of innovative cardiovascular medicines. Milestone’s lead product candidate, etripamil, is a novel, potent short-acting calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

RDY Core

Annual filing released 2025-06-06 · GPT 6 Luna

This segment consists of our business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of our biologics business, and the portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category (the “NRT Business”) that we recently acquired is also included in this segment. Pharmaceutical Services and Active Ingredients

We develop, manufacture, and market a portfolio of high-quality generic drugs at an affordable price. We seek to have a portfolio of credible brands, focused on delivering first-to-market, differentiated products to doctors and patients in both branded and unbranded generics markets. Our vertical integration helps ensure that quality products are always available to patients. We have also entered into strategic partnerships with third parties to sell our products in markets where we do not have our own sales and distribution operations. · Biosimilars:

MIST Core

Annual filing released 2025-03-13 · GPT 6 Luna

prevent new investors from influencing significant corporate decisions. 6 Table of Contents PART I ITEM 1. BUSINESS Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our objective is to commercialize and develop CARDAMYST (also known as etripamil) in the United States as a fast-acting, portable nasal spray treatment for use by patients anywhere, anytime an attack of supraventricular tachycardia, or “SVT” occurs. We are also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate, or “AFib-RVR.” CARDAMYSTTM (etripamil) nasal spray

CARDAMYSTTM (etripamil) nasal spray We designed the molecule of etripamil, and we are developing the drug, a novel, potent and rapid-onset calcium channel blocker, as a nasal spray to be administered by the patient to terminate episodes of transient cardiovascular conditions as they occur. Rapid pharmacological action is both appropriate and sufficient to resolve an episode of SVT. We have completed Phase 3 development for PSVT.

RDY Core

Annual filing released 2025-06-06 · GPT 6 Luna

This segment consists of our business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of our biologics business, and the portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category (the “NRT Business”) that we recently acquired is also included in this segment. Pharmaceutical Services and Active Ingredients

We develop, manufacture, and market a portfolio of high-quality generic drugs at an affordable price. We seek to have a portfolio of credible brands, focused on delivering first-to-market, differentiated products to doctors and patients in both branded and unbranded generics markets. Our vertical integration helps ensure that quality products are always available to patients. We have also entered into strategic partnerships with third parties to sell our products in markets where we do not have our own sales and distribution operations. · Biosimilars:

MIST Not tagged

Annual filing released 2025-03-13 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

RDY Material

Annual filing released 2025-06-06 · GPT 6 Luna

This segment consists of our business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of our biologics business, and the portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category (the “NRT Business”) that we recently acquired is also included in this segment. Pharmaceutical Services and Active Ingredients

During the year ended March 31, 2025, we continued to build out our presence in the Self-care and Wellness space by focusing on building out our consumer health brands as part of our innovation initiatives. This included ramping our e-commerce only brand HealthCareAisle, which included growing our share on base products and launching of multiple new products on the Amazon marketplace. We also started renovating our existing brands of Doan’s® and Habitrol® and we also completed the integration of the MenoLabs® business, which we acquired from Amyris in its Chapter 11 bankruptcy sales process back in Dec 2023. MenoLabs® is a leading women’s health and dietary supplement branded portfolio which includes multiple branded products designed to provide health support and address symptoms of perimenopause and menopause.

MIST Not tagged

Annual filing released 2025-03-13 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

RDY Core

Annual filing released 2025-06-06 · GPT 6 Luna

Manufacturing for our Global Generics segment entails converting API into finished dosages. As of March 31, 2025, we had ten manufacturing facilities within this segment located in India, including four in a Special Economic Zone. All of the facilities are designed in accordance with and are compliant with current cGMP requirements and are used for the manufacture of tablets, hard gelatin capsules, injections, liquids and creams for sale in India as well as other markets. All of our manufacturing sites’ laboratories and facilities are designed and maintained to meet increasingly stringent requirements of safety and quality. Each of our sites outside of India is approved by the respective regulatory body in the jurisdiction it is located.

We manufacture most of our finished products at these facilities and also use contract manufacturing arrangements as we determine necessary. For each of our products, we continue to identify, upgrade and develop alternate vendors as part of risk mitigation and continual improvement.

MIST Not tagged

Annual filing released 2025-03-13 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

RDY Material

Annual filing released 2025-06-06 · GPT 6 Luna

In April 2024, we entered into a definitive agreement with Nestlé India Limited (“Nestlé India”), for manufacturing, developing, promoting, marketing, selling, distributing, and commercializing nutraceutical products and supplements in India and other geographies as may be agreed by the parties. The aforesaid business activities are carried out through Dr. Reddy’s Nutraceuticals Limited (the “Nutraceuticals subsidiary”) which was incorporated on March 14, 2024. Subsequently, the Nutraceuticals subsidiary’s name was changed to Dr. Reddy’s and Nestlé Health Science Limited on June 13, 2024. The closing conditions were satisfied, and the transaction was completed on August 1, 2024. This arrangement is strategically important for both companies as it allows to combine their complementary strengths and expand their reach in the nutraceutical market.

During the year ended March 31, 2025, we continued to build out our presence in the Self-care and Wellness space by focusing on building out our consumer health brands as part of our innovation initiatives. This included ramping our e-commerce only brand HealthCareAisle, which included growing our share on base products and launching of multiple new products on the Amazon marketplace. We also started renovating our existing brands of Doan’s® and Habitrol® and we also completed the integration of the MenoLabs® business, which we acquired from Amyris in its Chapter 11 bankruptcy sales process back in Dec 2023. MenoLabs® is a leading women’s health and dietary supplement branded portfolio which includes multiple branded products designed to provide health support and address symptoms of perimenopause and menopause.

MIST Not tagged

Annual filing released 2025-03-13 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

RDY Material

Annual filing released 2025-06-06 · GPT 6 Luna

This segment consists of our other business operations which includes our wholly-owned subsidiaries, Aurigene Oncology Limited (“AOL”) (formerly Aurigene Discovery Technologies Limited) and our Proprietary Products business. AOL is a specialized biotechnology company engaged in discovery and early clinical development of novel, best-in-class therapies in the fields of oncology and inflammation. AOL works with established pharmaceutical and biotechnology companies through customized models of drug-discovery collaborations. Our Proprietary Products business is focused on the research, development and commercialization of differentiated formulations and we derive revenues from such assets through event specific milestones and subsequent royalties, if any. Our key markets include the United States, India, Russia and other countries of the former Soviet Union, and Europe. OUR STRATEGY

AOL is a clinical stage biotech company committed to developing innovative and effective cancer therapeutics. AOL has successfully discovered 21 novel chemical entities for clinical development. Some of these molecules were developed in collaboration with global pharmaceutical and biotechnology companies while others were developed independently. We have out-licensed several first-in-class and best-in-class assets to pharmaceutical and biotechnology companies for global clinical development, while undertaking clinical proof of concept studies for a few programs on our own. Over the years, AOL has developed multiple discovery platforms, including kinase inhibitors, targeted protein degraders, antibody engineering and cell and gene therapy, resulting in a pipeline of first-in-class and best-in-class assets. Proprietary Products: